Ad Header



The Pulse of the Pharmaceutical Industry

Novo launches Saxenda in US, sees more launches in 2015

Written by: | | Dated: Wednesday, April 22nd, 2015

(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

The company has said previously it expects sales from the drug to eventually reach $1 billion a year.

It said in a statement on Wednesday it would launch Saxenda in other markets later this year.

Novo plans to use 500 of its 3,000-strong U.S. sales force to promote Saxenda, but has warned a ramp-up of sales would be slow.

Deputy Chief Executive Kaare Schultz told Reuters last month safety concerns over past weight-loss medicines as well as reimbursement issues meant it would take a while to get sales of Saxenda going.

Shares in Novo, by far the largest company in the Nordic region by market capitalization, were down 0.46 percent to 391.39 crowns at 0930 EDT.

They hit all-time highs last month on news the company would resubmit its Tresiba insulin to U.S. regulators for approval.


(Reporting by Sabina Zawadzki and Teis Jensen; Editing by Mark Potter)


Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom